<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.bpsmedicine.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>BioPsychoSocial Medicine - Latest Articles</title>
        <link>http://www.bpsmedicine.com</link>
        <description>The latest research articles published by BioPsychoSocial Medicine</description>
        <dc:date>2013-04-23T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.bpsmedicine.com/content/7/1/10" />
                                <rdf:li rdf:resource="http://www.bpsmedicine.com/content/7/1/9" />
                                <rdf:li rdf:resource="http://www.bpsmedicine.com/content/7/1/8" />
                                <rdf:li rdf:resource="http://www.bpsmedicine.com/content/7/1/7" />
                                <rdf:li rdf:resource="http://www.bpsmedicine.com/content/7/1/3" />
                                <rdf:li rdf:resource="http://www.bpsmedicine.com/content/7/1/6" />
                                <rdf:li rdf:resource="http://www.bpsmedicine.com/content/7/1/5" />
                                <rdf:li rdf:resource="http://www.bpsmedicine.com/content/7/1/4" />
                                <rdf:li rdf:resource="http://www.bpsmedicine.com/content/7/1/2" />
                                <rdf:li rdf:resource="http://www.bpsmedicine.com/content/7/1/1" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.bpsmedicine.com/content/7/1/10">
        <title>Psychosocial and cognitive function in children with nephrotic syndrome: association with disease and treatment variables</title>
        <description>Background:
To investigate possible differences in emotional/behavioral problems and cognitive function in children with nephrotic syndrome compared to healthy controls and to examine the effect of disease-specific and steroid treatment-specific characteristics on the abovementioned variables.
Methods:
Forty-one patients with nephrotic syndrome (23 boys, age range: 4.4-15.2 years) and 42 sex- and age-matched healthy control subjects (20 boys, age range: 4.1-13.4 years) were enrolled in the study. Disease (severity, age of diagnosis, duration) and steroid treatment (total duration, present methylprednisolone dose and duration of present dose) data were collected. In order to assess children&#8217;s emotional/behavioral problems, the Child Behavior Checklist was administered. The Wechsler Intelligence Scale for Children &#8211; Third Edition was administered to assess Full-Scale, Verbal, and Performance intelligence quotient (IQ) scores.
Results:
The patients presented with more internalizing problems (P&#8201;=&#8201;0.015), including withdrawal (P&#8201;=&#8201;0.012) and somatic complaints (P&#8201;=&#8201;0 .011), but not more anxiety/depression or externalizing problems. A significant association was found between severity of disease and somatic complaints (P&#8201;=&#8201;0.017) as well as externalizing problems (P&#8201;=&#8201;0.030). Years of illness were significantly more in those presenting with abnormal anxiety/depression (P&#8201;=&#8201;0.011). Duration of steroid medication was significantly higher among those presenting with abnormal anxiety/depression (P&#8201;=&#8201;0.011) and externalizing problems (P&#8201;=&#8201;0.039). IQ was not associated significantly with disease or steroid treatment variables.
Conclusions:
Psychosocial factors and outcomes may be important correlates of children&#8217;s nephrotic syndrome and potential targets of thorough assessment and treatment.</description>
        <link>http://www.bpsmedicine.com/content/7/1/10</link>
                <dc:creator>Panagiota Manti</dc:creator>
                <dc:creator>George Giannakopoulos</dc:creator>
                <dc:creator>Elena Giouroukou</dc:creator>
                <dc:creator>Helen Georgaki-Angelaki</dc:creator>
                <dc:creator>Constantinos Stefanidis</dc:creator>
                <dc:creator>Andromahi Mitsioni</dc:creator>
                <dc:creator>Nikolaos Stergiou</dc:creator>
                <dc:creator>Constantinos Mihas</dc:creator>
                <dc:creator>George Chrousos</dc:creator>
                <dc:creator>Maria Magiakou</dc:creator>
                <dc:creator>Gerasimos Kolaitis</dc:creator>
                <dc:source>BioPsychoSocial Medicine 2013, null:10</dc:source>
        <dc:date>2013-04-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1751-0759-7-10</dc:identifier>
                                <prism:require>/content/figures/1751-0759-7-10-toc.gif</prism:require>
                <prism:publicationName>BioPsychoSocial Medicine</prism:publicationName>
        <prism:issn>1751-0759</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2013-04-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.bpsmedicine.com/content/7/1/9">
        <title>Prolonged post-hyperventilation apnea in two young adults with hyperventilation syndrome</title>
        <description>Background:
The prognosis of hyperventilation syndrome (HVS) is generally good. However, it is important to proceed with care when treating HVS because cases of death following hyperventilation have been reported. This paper was done to demonstrate the clinical risk of post-hyperventilation apnea (PHA) in patients with HVS.Case presentationWe treated two patients with HVS who suffered from PHA. The first, a 21-year-old woman, had a maximum duration of PHA of about 3.5&#8201;minutes and an oxygen saturation (SpO2) level of 60%. The second patient, a 22-year-old woman, had a maximum duration of PHA of about 3&#8201;minutes and an SpO2 level of 66%. Both patients had loss of consciousness and cyanosis. Because there is no widely accepted regimen for treating patients with prolonged PHA related to HVS, we administered artificial ventilation to both patients using a bag mask and both recovered without any after effects.
Conclusion:
These cases show that some patients with HVS develop prolonged PHA or severe hypoxia, which has been shown to lead to death in some cases. Proper treatment must be given to patients with HVS who develop PHA to protect against this possibility. If prolonged PHA or severe hypoxemia arises, respiratory assistance using a bag mask must be done immediately.</description>
        <link>http://www.bpsmedicine.com/content/7/1/9</link>
                <dc:creator>Takao Munemoto</dc:creator>
                <dc:creator>Akinori Masuda</dc:creator>
                <dc:creator>Nobuatsu Nagai</dc:creator>
                <dc:creator>Muneki Tanaka</dc:creator>
                <dc:creator>Soejima Yuji</dc:creator>
                <dc:source>BioPsychoSocial Medicine 2013, null:9</dc:source>
        <dc:date>2013-04-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1751-0759-7-9</dc:identifier>
                                <prism:require>/content/figures/1751-0759-7-9-toc.gif</prism:require>
                <prism:publicationName>BioPsychoSocial Medicine</prism:publicationName>
        <prism:issn>1751-0759</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2013-04-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.bpsmedicine.com/content/7/1/8">
        <title>Neuroimaging studies of alexithymia: physical, affective, and social perspectives</title>
        <description>Alexithymia refers to difficulty in identifying and expressing one&#8217;s emotions, and it is related to disturbed emotional regulation. It was originally proposed as a personality trait that plays a central role in psychosomatic diseases. This review of neuroimaging studies on alexithymia suggests that alexithymia is associated with reduced neural responses to emotional stimuli from the external environment, as well as with reduced activity during imagery, in the limbic and paralimbic areas (i.e., amygdala, insula, anterior/posterior cingulate cortex). In contrast, alexithymia is also known to be associated with enhanced neural activity in somatosensory and sensorimotor regions, including the insula. Moreover, neural activity in the medial, prefrontal, and insula cortex was lowered when people with alexithymia were involved in social tasks. Because most neuroimaging studies have been based on sampling by self-reported questionnaires, the contrasted features of neural activities in response to internal and external emotional stimuli need to be elucidated. The social and emotional responses of people with alexithymia are discussed and recommendations for future research are presented.</description>
        <link>http://www.bpsmedicine.com/content/7/1/8</link>
                <dc:creator>Yoshiya Moriguchi</dc:creator>
                <dc:creator>Gen Komaki</dc:creator>
                <dc:source>BioPsychoSocial Medicine 2013, null:8</dc:source>
        <dc:date>2013-03-28T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1751-0759-7-8</dc:identifier>
                                <prism:require>/content/figures/1751-0759-7-8-toc.gif</prism:require>
                <prism:publicationName>BioPsychoSocial Medicine</prism:publicationName>
        <prism:issn>1751-0759</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2013-03-28T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.bpsmedicine.com/content/7/1/7">
        <title>Psychological stress contributed to the development of low-grade fever in a patient with chronic fatigue syndrome: a case report</title>
        <description>Background:
Low-grade fever is a common symptom in patients with chronic fatigue syndrome (CFS), but the mechanisms responsible for its development are poorly understood. We submit this case report that suggests that psychological stress contributes to low-grade fever in CFS.Case presentationA 26-year-old female nurse with CFS was admitted to our hospital. She had been recording her axillary temperature regularly and found that it was especially high when she felt stress at work. To assess how psychological stress affects temperature and to investigate the possible mechanisms for this hyperthermia, we conducted a 60-minute stress interview and observed the changes in the following parameters: axillary temperature, fingertip temperature, systolic blood pressure, diastolic blood pressure, heart rate, plasma catecholamine levels, and serum levels of interleukin (IL)-1&#946; and IL-6 (pyretic cytokines), tumor necrosis factor-&#945; and IL-10 (antipyretic cytokines). The stress interview consisted of recalling and talking about stressful events. Her axillary temperature at baseline was 37.2&#176;C, increasing to 38.2&#176;C by the end of the interview. In contrast, her fingertip temperature decreased during the interview. Her heart rate, systolic and diastolic blood pressures, and plasma levels of noradrenaline and adrenaline increased during the interview; there were no significant changes in either pyretic or antipyretic cytokines during or after the interview.
Conclusions:
A stress interview induced a 1.0&#176;C increase in axillary temperature in a CFS patient. Negative emotion-associated sympathetic activation, rather than pyretic cytokine production, contributed to the increase in temperature induced by the stress interview. This suggests that psychological stress may contribute to the development or the exacerbation of low-grade fever in some CFS patients.</description>
        <link>http://www.bpsmedicine.com/content/7/1/7</link>
                <dc:creator>Takakazu Oka</dc:creator>
                <dc:creator>Yoshio Kanemitsu</dc:creator>
                <dc:creator>Nobuyuki Sudo</dc:creator>
                <dc:creator>Haruo Hayashi</dc:creator>
                <dc:creator>Kae Oka</dc:creator>
                <dc:source>BioPsychoSocial Medicine 2013, null:7</dc:source>
        <dc:date>2013-03-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1751-0759-7-7</dc:identifier>
                                <prism:require>/content/figures/1751-0759-7-7-toc.gif</prism:require>
                <prism:publicationName>BioPsychoSocial Medicine</prism:publicationName>
        <prism:issn>1751-0759</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2013-03-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.bpsmedicine.com/content/7/1/3">
        <title>Reviewer acknowledgement 2012</title>
        <description>The editors of BioPsychoSocial Medicine would like to thank all our reviewers who have contributed to the journal in Volume 6 (2012).</description>
        <link>http://www.bpsmedicine.com/content/7/1/3</link>
                <dc:creator>Koji Tsuboi</dc:creator>
                <dc:source>BioPsychoSocial Medicine 2013, null:3</dc:source>
        <dc:date>2013-02-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1751-0759-7-3</dc:identifier>
                                <prism:require>/content/figures/1751-0759-7-3-toc.gif</prism:require>
                <prism:publicationName>BioPsychoSocial Medicine</prism:publicationName>
        <prism:issn>1751-0759</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2013-02-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.bpsmedicine.com/content/7/1/6">
        <title>A randomized, double-masked, placebo-controlled crossover trial on the effects of L-ornithine on salivary cortisol and feelings of fatigue of flushers the morning after alcohol consumption</title>
        <description>Background:
Residual alcohol effects on physiological and psychological symptoms are commonly experienced the morning after alcohol consumption. The purpose of this study was to assess the effects of L-ornithine on subjective feelings and salivary stress markers the morning after alcohol consumption and to investigate whether L-ornithine acutely accelerates ethanol metabolism.
Methods:
This study had a randomized, placebo-controlled, double-masked crossover design. Subjects were all healthy Japanese adults with the &#8216;flusher&#8217; phenotype for alcohol tolerance. In experiment 1, 11 subjects drank 0.4 g/kg body weight alcohol 1.5 h before their usual bedtime. Half an hour after drinking, they ingested either a placebo or 400 mg ornithine. The next morning on awakening, subjects completed a questionnaire containing a visual analog scale (VAS), the Oguri-Shirakawa-Azumi sleep inventory MA version (OSA-MA), and a profile of mood states (POMS) and collected a saliva sample for measurement of salivary stress markers (cortisol, secretory immunoglobulin A, and &#945;-amylase). In experiment 2, placebo or 400 mg ornithine were administrated to 16 subjects both before and after drinking, and the feeling of drunkenness, breath ethanol concentration and one-leg standing time were repeatedly investigated until 180 min after alcohol consumption.
Results:
There were significant decreases in &#8220;awareness&#8221;, &#8220;feeling of fatigue&#8221; and &#8220;lassitude&#8221; VAS scores and in &#8220;anger-hostility&#8221; and &#8220;confusion&#8221; POMS scores and a significant increase in &#8220;sleep length&#8221; in the OSA-MA test. Salivary cortisol concentrations on awakening were reduced after ornithine supplementation. There were no differences between ornithine and placebo in any of the subjective or physiological parameters of acute alcohol metabolism.
Conclusions:
Taking 400 mg ornithine after alcohol consumption improved various negative feelings and decreased the salivary stress marker cortisol the next morning. These effects were not caused by an increase in acute alcohol metabolism.</description>
        <link>http://www.bpsmedicine.com/content/7/1/6</link>
                <dc:creator>Takeshi Kokubo</dc:creator>
                <dc:creator>Emiko Ikeshima</dc:creator>
                <dc:creator>Takayoshi Kirisako</dc:creator>
                <dc:creator>Yutaka Miura</dc:creator>
                <dc:creator>Masahisa Horiuchi</dc:creator>
                <dc:creator>Akira Tsuda</dc:creator>
                <dc:source>BioPsychoSocial Medicine 2013, null:6</dc:source>
        <dc:date>2013-02-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1751-0759-7-6</dc:identifier>
                                <prism:require>/content/figures/1751-0759-7-6-toc.gif</prism:require>
                <prism:publicationName>BioPsychoSocial Medicine</prism:publicationName>
        <prism:issn>1751-0759</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2013-02-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.bpsmedicine.com/content/7/1/5">
        <title>Relationship between autonomic cardiovascular control, case definition, clinical symptoms, and functional disability in adolescent chronic fatigue syndrome: An exploratory study</title>
        <description>Chronic Fatigue Syndrome (CFS) is characterized by severe impairment and multiple symptoms. Autonomic dysregulation has been demonstrated in several studies. We aimed at exploring the relationship between indices of autonomic cardiovascular control, the case definition from Centers for Disease Control and Prevention (CDC criteria), important clinical symptoms, and disability in adolescent chronic fatigue syndrome. 38 CFS patients aged 12&#8211;18 years were recruited according to a wide case definition (ie. not requiring accompanying symptoms) and subjected to head-up tilt test (HUT) and a questionnaire. The relationships between variables were explored with multiple linear regression analyses. In the final models, disability was positively associated with symptoms of cognitive impairments (p&lt;0.001), hypersensitivity (p&lt;0.001), fatigue (p=0.003) and age (p=0.007). Symptoms of cognitive impairments were associated with age (p=0.002), heart rate (HR) at baseline (p=0.01), and HR response during HUT (p=0.02). Hypersensitivity was associated with HR response during HUT (p=0.001), high-frequency variability of heart rate (HF-RRI) at baseline (p=0.05), and adherence to the CDC criteria (p=0.005). Fatigue was associated with gender (p=0.007) and adherence to the CDC criteria (p=0.04). In conclusion, a) The disability of CFS patients is not only related to fatigue but to other symptoms as well; b) Altered cardiovascular autonomic control is associated with certain symptoms; c) The CDC criteria are poorly associated with disability, symptoms, and indices of altered autonomic nervous activity.</description>
        <link>http://www.bpsmedicine.com/content/7/1/5</link>
                <dc:creator>Vegard Wyller</dc:creator>
                <dc:creator>Ingrid Helland</dc:creator>
                <dc:source>BioPsychoSocial Medicine 2013, null:5</dc:source>
        <dc:date>2013-02-07T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1751-0759-7-5</dc:identifier>
                                <prism:require>/content/figures/1751-0759-7-5-toc.gif</prism:require>
                <prism:publicationName>BioPsychoSocial Medicine</prism:publicationName>
        <prism:issn>1751-0759</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2013-02-07T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.bpsmedicine.com/content/7/1/4">
        <title>Younger and older chronic somatoform pain patients in psycho-diagnostics, physician-patient relationship and treatment outcome</title>
        <description>IntroductionPatients with chronic pain are found with highly variable clinical presentation and differing physical complaints. They are seen as a heterogenic group. Based on clinical observations, elderly patients seem to differ from younger patients with chronic pain. We examined whether there were systematic differences between young and old pain patients.
Methods:
As part of a routine evaluation of university hospital care, a newly developed psychosomatic treatment model for chronic somatoform pain disorders was examined. The basis for treatment efficacy was a target-oriented, specific somatic and psychological intervention that included a stable physician-patient relationship. Particular attention was paid to differences in treatment outcome with regard to changes in both physical and psychopathological symptom levels. We hypothesised that younger pain patients had higher psychological burden and benefitted more from our treatment than older pain patients.
Results:
Overall, 179 inpatients (57.5% women) with chronic pain were examined (age between 16 and 79 years). The group as a whole yielded high scores on the somatisation dimension (SCL-90) and showed a considerable amount of psychopathological symptoms, such as depressive mood and anxiety (HADS) and a great emotional instability (FPI-R). Age differences were only found with regards to patients&#8217; degree of aggression (SCl-90): younger patients showed higher aggressive tendencies than older ones (p&lt; 0.05). The treatment offered helped patients in both age groups especially with regard to reduction of depressive mood (HADS, p&lt; 0.01) and anxiety levels (HADS, p&lt; 0.01). Regression analysis showed different age groups and gender as significant predictors of anxiety reduction under therapy (R2=.108; model: p&lt; 0.01).Discussion and conclusionResults show that younger chronic pain patients suffer more from a considerable amount of psychological distress than older ones, but our treatment approach was equally effective in both groups. However, age and gender differences, as well as the patient&#8217;s baseline level of anxiety influenced the outcome. These factors need to be studied in future research.</description>
        <link>http://www.bpsmedicine.com/content/7/1/4</link>
                <dc:creator>Bernd Bergander</dc:creator>
                <dc:creator>Laurence Erdur</dc:creator>
                <dc:creator>Bettina Kallenbach-Dermutz</dc:creator>
                <dc:creator>Hans-Christian Deter</dc:creator>
                <dc:source>BioPsychoSocial Medicine 2013, null:4</dc:source>
        <dc:date>2013-02-04T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1751-0759-7-4</dc:identifier>
                                <prism:require>/content/figures/1751-0759-7-4-toc.gif</prism:require>
                <prism:publicationName>BioPsychoSocial Medicine</prism:publicationName>
        <prism:issn>1751-0759</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2013-02-04T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.bpsmedicine.com/content/7/1/2">
        <title>New year address on the state of psychosomatic medicine in Japan</title>
        <description>First Paragraph - article has no abstract.The Japanese Society of Psychosomatic Medicine was founded in 1959, and its first congress was held in 1960, with fewer than 100 members.  The society has grown tremendously since then, both in terms of scope and size.  In 2012, we had 3,600 members.  We have hosted the World Congress of Psychosomatic Medicine two times, first in 1977 in Kyoto, then in 2005 in Kobe, where we were very honored by the attendance of the Emperor and Empress and privileged to hear the Emperors encouraging speech.</description>
        <link>http://www.bpsmedicine.com/content/7/1/2</link>
                <dc:creator>Chiharu Kubo</dc:creator>
                <dc:source>BioPsychoSocial Medicine 2013, null:2</dc:source>
        <dc:date>2013-01-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1751-0759-7-2</dc:identifier>
                                <prism:require>/content/figures/1751-0759-7-2-toc.gif</prism:require>
                <prism:publicationName>BioPsychoSocial Medicine</prism:publicationName>
        <prism:issn>1751-0759</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2013-01-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.bpsmedicine.com/content/7/1/1">
        <title>The alexithymic brain: the neural pathways linking alexithymia to physical disorders</title>
        <description>Alexithymia is a personality trait characterized by difficulties in identifying and describing feelings and is associated with psychiatric and psychosomatic disorders. The mechanisms underlying the link between emotional dysregulation and psychosomatic disorders are unclear. Recent progress in neuroimaging has provided important information regarding emotional experience in alexithymia. We have conducted three brain imaging studies on alexithymia, which we describe herein. This article considers the role of emotion in the development of physical symptoms and discusses a possible pathway that we have identified in our neuroimaging studies linking alexithymia with psychosomatic disorders. In terms of socio-affective processing, alexithymics demonstrate lower reactivity in brain regions associated with emotion. Many studies have reported reduced activation in limbic areas (e.g., cingulate cortex, anterior insula, amygdala) and the prefrontal cortex when alexithymics attempt to feel other people&#8217;s feelings or retrieve their own emotional episodes, compared to nonalexithymics. With respect to primitive emotional reactions such as the response to pain, alexithymics show amplified activity in areas considered to be involved in physical sensation. In addition to greater hormonal arousal responses in alexithymics during visceral pain, increased activity has been reported in the insula, anterior cingulate cortex, and midbrain. Moreover, in complex social situations, alexithymics may not be able to use feelings to guide their behavior appropriately. The Iowa gambling task (IGT) was developed to assess decision-making processes based on emotion-guided evaluation. When alexithymics perform the IGT, they fail to learn an advantageous decision-making strategy and show reduced activity in the medial prefrontal cortex, a key area for successful performance of the IGT, and increased activity in the caudate, a region associated with impulsive choice. The neural machinery in alexithymia is therefore activated more on the physiologic, motor-expressive level and less in the cognitive-experiential domains of the emotional response system. Affects may play an important role in alleviating intrinsic physiologic reactions and adapting to the environment. Deficient development of emotional neural structures may lead to hypersensitivity to bodily sensations and unhealthy behaviors, a possible mechanism linking alexithymia to psychosomatic disorders.</description>
        <link>http://www.bpsmedicine.com/content/7/1/1</link>
                <dc:creator>Michiko Kano</dc:creator>
                <dc:creator>Shin Fukudo</dc:creator>
                <dc:source>BioPsychoSocial Medicine 2013, null:1</dc:source>
        <dc:date>2013-01-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1751-0759-7-1</dc:identifier>
                                <prism:require>/content/figures/1751-0759-7-1-toc.gif</prism:require>
                <prism:publicationName>BioPsychoSocial Medicine</prism:publicationName>
        <prism:issn>1751-0759</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2013-01-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
